文献速递白血病造血干细胞移植与细胞治疗

低剂量CD19靶向CAR-T细胞治疗51例难治或复发B细胞急性淋巴细胞白血病患者的高疗效与安全性

High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.
PubMed 文献 · Leukemia · 2017-05-15

研究纳入42例原发难治或血液学复发及9例流式微小残留病阳性B-ALL患者,接受优化二代CD19 CAR-T细胞治疗,输注剂量最初为0.05–14×10^5/kg,最近20例最终定为1×10^5/kg。可评估的40例R/R患者中36例(90%)达CR/CRi,9例FCM-MRD+患者均达MRD-,最近20例均达CR/CRi;多数仅轻中度CRS,8/51例出现癫痫但经早期干预缓解。

要点

  • 低剂量1×10^5/kg CD19 CAR-T对难治/复发B-ALL有效且安全。
  • 可评估R/R患者CR/CRi率90%(36/40),FCM-MRD+患者MRD-率100%(9/9)。
  • 27例CR/CRi桥接allo-HCT者中23例维持MRD-,未桥接者18例中9例复发。

核心结论

  • 低剂量1×10^5/kg CAR-T细胞治疗难治或复发B-ALL有效且安全,后续allo-HCT可能进一步降低复发率。

研究设计与样本

  • 研究治疗42例原发难治/血液学复发和9例流式微小残留病阳性(FCM-MRD+)B-ALL患者,采用优化二代CD19靶向CAR-T细胞。
  • CAR-T细胞输注剂量最初为0.05–14×10^5/kg,最近20例最终定为1×10^5/kg。

主要发现

  • 可评估的40例R/R患者中36例(90%)达完全缓解(CR)或伴计数未完全恢复的CR(CRi)。
  • 9例FCM-MRD+患者均达MRD-(9/9,100%)。
  • 最近20例患者均达CR/CRi。
  • 多数病例仅发生轻至中度细胞因子释放综合征(CRS)。
  • 51例中8例出现癫痫,经早期干预后缓解。

关键数值与推荐

  • 27例CR/CRi患者桥接allo-HCT后,23例维持MRD-,中位随访206(45–427)天。
  • 18例CR/CRi患者未桥接allo-HCT,其中9例复发。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Refractory or relapsed B lymphoblastic leukemia (B-ALL) patients have a dismal outcome with current therapy. We treated 42 primary refractory/hematological relapsed (R/R) and 9 refractory minimal residual disease by flow cytometry (FCM-MRD+) B-ALL patients with optimized second generation CD19-directed CAR-T cells. The CAR-T-cell infusion dosages were initially ranged from 0.05 to 14 × 105/kg and were eventually settled at 1 × 105/kg for the most recent 20 cases. 36/40 (90%) evaluated R/R patients achieved complete remission (CR) or CR with incomplete count recovery (CRi), and 9/9 (100%) FCM-MRD+ patients achieved MRD-. All of the most recent 20 patients achieved CR/CRi. Most cases only experienced mild to moderate CRS. 8/51 cases had seizures that were relieved by early intervention. Twenty three of twenty seven CR/CRi patients bridged to allogeneic hematopoietic stem cell transplantation (allo-HCT) remained in MRD- with a median follow-up time of 206 (45-427) days, whereas 9 of 18 CR/CRi patients without allo-HCT relapsed. Our results indicate that a low CAR-T-cell dosage of 1 × 105/kg, is effective and safe for treating refractory or relapsed B-ALL, and subsequent allo-HCT could further reduce the relapse rate.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Pan J, Yang JF, Deng BP, et al. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia. 2017. PMID: 28490811. doi:10.1038/leu.2017.145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。